Recognising the potential of the treatment, international animal health product manufacturer, Fort Dodge Animal Health, has licensed Dr Hall's treatment via UQ's commercial arm, UniQuest Pty Ltd.Fort Dodge will test the treatment's effectiveness in horses and develop it for commercial sale to the equine industry, according to UniQuest Managing Director, David Henderson. "Horses are a large group affected by West Nile virus in the U.S., and Dr Hall's treatment will complement Fort Dodge Animal Health's equine vaccine that protects against the disease," Mr Henderson said.
In addition, Dr Hall is developing a West Nile vaccine for humans with UQ's Associate Professor Alex Khromykh, which is undergoing preclinical trials. A West Nile diagnostic reagent also developed by Dr Hall has been licensed for sale in the U.S. and will be used to track the spread of the disease in animals and birds in North America. Dr Hall said it was very satisfying to see his research being used in North America, where West Nile virus was a serious problem. "Unfortunately, it is only a matter of time before West Nile virus hits Australian shores but hopefully my research will help reduce the impact of the disease."
Source: Research Australia
Bio.com
May 24, 2005
Original web page at Bio.com



